Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Among patients with high tumor PD-L1 expression, Libtayo lowered mortality by 43%.
Cemiplimab is the first treatment for metastatic or locally advanced cutaneous squamous cell carcinoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.